Skip to main content

Table 1 Baseline AAV patient characteristics by treatment group

From: Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Variables

Rituximab group, n = 34

IV-CY group, n = 20

p value

Age (years)

70.4 (8.4)

70.9 (8.4)

0.86

Gender, n (% female)

19 (55.9%)

10 (50.0%)

0.78

Disease duration (month)

3 (2–5)

4 (1–7)

0.93

New onset, n (%)

34 (100.0%)

20 (100.0%)

1.00

ANCA-positive at diagnosis, n (%)

 Proteinase 3 ANCA

4 (11.8%)

0 (0.0%)

0.28

 Myeloperoxidase-ANCA

26 (76.5%)

18 (90.0%)

0.29

 Proteinase 3 + myeloperoxidase-ANCA

3 (8.8%)

1 (5.0%)

1.00

ANCA-associated vasculitis type, n (%)

  

0.24

 MPA

19 (55.9%)

15 (75.0%)

 

 GPA

15 (44.1%)

5 (25.0%)

 

BVAS

17.4 (6.5)

15.1 (4.6)

0.15

Organ involvement, n

 Cutaneous involvement

2

0

0.52

 Mucous membranes and eyes

3

2

1.00

 Ear, nose, and throat

11

6

1.00

 Pulmonary involvement

27

15

0.74

 Renal involvement

28

18

0.75

 Neurologic involvement

11

3

0.21

GC dose at base line

56.3 (11.5)

61.6 (16.7)

0.17

  1. Values listed as mean (SD) and median (minimum-maximum) unless otherwise stated. The statistical difference was determined by Student’s t test and Mann-Whitney’s U test, with chi-square test used for nominal variables. Difference with p < 0.05 was considered significant